Sector News

Shire opens $1B plant to make rare disease drugs

October 15, 2018
Life sciences

Shire’s $1 billion plasma fractionation plant in Georgia has gone through three owners already since it was envisioned and will soon have a fourth. But after six years, it is now officially open.

The company held a kickoff ceremony at the plant in Covington on Thursday, according to The Covington News. In an email, the company confirmed that the plant currently has about 900 employees and is expected to have about 1,500 when it is fully operational.

The 1 million-square-foot facility was announced in 2012 when Baxalta was still the drug unit of Baxter International. Baxter spun the drug unit off into Baxalta in 2014, and Shire bought Baxalta in a $32 billion deal in 2016 in a move to broaden its offerings. The plant is soon expected to have a fourth owner after Japan’s Takeda in May made a $62 billion deal to buy Dublin-based Shire.

Through all of that, patients have been “the ultimate inspiration for everything,” Carlos Soto, Shire’s vice president of manufacturing operations, said at the opening, the newspaper reported.

The company will make immunoglobulin products there to help patients with primary immune deficiency disorders. The company last year said it has filed its first submission to the FDA for the plant, seeking the transfer of production of Gammagard Liquid, a replacement therapy for primary humoral immunodeficiency. Shire in June won FDA approval for the product.

Shire expects to make a second submission to the FDA this year for development of its albumin therapy at the Covington facility. Shire’s albumin therapy is primarily used as plasma-volume replacement therapy in immune disorders, trauma and other critical conditions, the company said.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach